Goldman Sachs sets USD 441 target on Krystal Biotech
Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash
Goldman Sachs resumed coverage of Krystal Biotech (KRYS) with a Buy rating and a USD 441 price target, citing the company's commercial execution and pipeline potential, particularly for its VYJUVEK product. The analyst highlighted strong gross margins and the value of the genetic medicine pipeline despite a recent revenue shortfall. Krystal Biotech's third-quarter results, scheduled for November 2, 2026, are the next test for the stock.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.